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Objectives: Low uptake of cancer screening services is a global concern. Our aim was to understand factors that influence the
screening decision, including screening and treatment subsidies and a gain-frame message designed to present screening as a
win–win.
Methods: We analyzed preferences for mammography and Pap smear among women in Singapore by means of discrete
choice experiments while randomly exposing half of respondents to a gain-framed public health message promoting the
benefits of screening.
Results: Results showed that the message did not influence stated uptake, and given the levels shown, respondents were
influenced more by treatment attributes, including effectiveness and out-of-pocket cost should they test positive, than by
screening attributes, including the offer of a monetary incentive for screening. Respondents also underestimated the
survival chances of screen-detected breast and cervical cancers.
Conclusions: Combined, these findings suggest that correcting misconceptions about screen-detected cancer prognosis or
providing greater financial protection for those who test positive could be more effective and more cost-effective than
subsidizing screening directly in increasing screening uptakes.
Keywords: breast cancer, cancer screening, cervical cancer, discrete choice experiments, uptake simulation.
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Cancer is a leading cause of morbidity and mortality world-
wide. In 2018, more than 18.1 million people were diagnosed with
cancer and more than 9.6 million cancer deaths were reported.1
The likelihood of complete recovery is greatest for those diag-
nosed at earlier stages, whereas survival drops markedly for those
diagnosed in later stages when cancer has progressed.2-4 The
rationale for screening is to identify and treat cancers before they
progress.
Mammography and Pap smear are the two most common
screening services for women. In Singapore, the focus of this
study, the Health Promotion Board (HPB) recommends women
aged 50 to 69 to screen every 2 years, and women aged 40 to 49
with higher cancer risk to screen every year.5 HPB further rec-
ommends Pap smears for women aged 25 to 69 who have ever
had sexual intercourse to screen every 3 years.5 Despite the HPBss correspondence to: Marcel Bilger, PhD, Health Economics and Policy, Vie
delsplatz 1, 1020 Vienna, Austria. Email: marcel.bilger@wu.ac.at
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cess article under the CC BY license (http://creativecommons.org/licenses/brecommendations, screening rates for both services are low. In
2016, only 38.6% of women aged 50 to 69 underwent mammog-
raphy screening within the last 2 years and 50.7% of eligible
women aged 25 to 69 underwent Pap smear screening within the
last 3 years.6 Incomplete screening uptake is not unique to
Singapore, although some countries screen at much higher
rates.7,8 These cross-country differences suggest opportunities to
increase rates above current levels in Singapore.
A large body of literature has used discrete choice experiments
(DCEs) to understand preferences for cancer screening services
and to identify strategies to increase screening uptake.9,10 DCEs
ask respondents to choose between hypothetical alternatives (eg,
different health services) described through a set of attributes (eg,
cost, quality, safety) that vary according to predefined levels. They
are appealing to study health screenings because only limited
market data exist to estimate their demand and the factors that
influence it.nna University of Economics and Business, Building D4, Office 3.280,
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
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on the features of the screening services (eg, procedure, accuracy,
cost). Other factors, however, such as costs associated with
treatment, might be equally or even more salient.11-13 The DCEs
we employ are novel in that they combine traditional screening
attributes with treatment attributes that have also been posited to
influence the screening decision.
Our first objective was to determine which factors matter most
in the decision to undergo cancer screening, with special
emphasis on the comparison between screening and treatment
outcome attributes and whether a monetary incentive to
encourage screening would increase stated uptake. Our second
objective was to test the effectiveness of a gain-frame message on
the benefits of screening that mimics current public health in-
formation campaigns in Singapore. Given that our DCEs mirror the
responses of informed respondents in terms of screening attri-
butes and treatment outcomes (as these are presented in the DCE
task), the question we asked is whether there is still a role for
targeted messaging to influence uptake. A third objective is to
simulate the effect of 2 strategies aimed at increasing screening
uptake. The first aims to quantify the effect on uptake of correcting
respondents’ large misconceptions for screen-detected cancer
survival rates. The second strategy is a budget-neutral reallocation
of screening subsidies towards lower treatment costs for the
subset of screened patients who test positive, as the latter might
be a more effective use of public money than subsidizing
screening itself in settings with high copayment rates.
To conduct these analyses, we employed 2 randomized
controlled DCEs: one for mammography and another for Pap
smear, with nationally representative samples of working age
women living in Singapore aged 40 to 64 and 25 to 64. To assess
the effectiveness of messaging, we randomly allocated half the
respondents to a group that we subjected to the message and half
to a control group with no message.
Methods
Selection of the Attributes and Levels for the DCE
We based attribute selection on both a systematic literature
review of DCEs on preferences for cancer screening (seeTable 1. Cancer screening attributes and levels: mammography and
Attributes Levels
1 2
Mammography
Discomfort or pain during
mammography
Discomfort Pain
Chance of false cancer diagnosis 5% 15%
Out-of-pocket payment or reward for
screening
Receive $50 Free-of-cha
Chance of surviving breast cancer 25% 50%
Permanent changes to breast None Change in f
Total out-of-pocket cost of treatment $0 $50 000
Pap Smear
Choice of practitioner's sex Choice No choice
Chance of false cancer diagnosis 5% 15%
Out-of-pocket payment or reward for
screening
Receive $50 Free-of-cha
Chance of surviving cervical cancer 25% 50%
Permanent sexual or reproductive
problems
None Sexual diffi
Total out-of-pocket cost of treatment $0 $50 000Appendix Table 1 in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2020.06.004) and on 8 focus group in-
terviews of 8 women each.14 We used the literature review to
identify the most frequently included attributes in past DCEs.
We shortlisted the following attributes based on their fre-
quency: accuracy, frequency of screening, screening cost, effec-
tiveness, pain or discomfort incurred during procedure, travel
time, and sex of the health practitioner. The most prominent
theme that we identified in our focus groups was the fear of
screening. We identified 2 broad categories of fear: fear of the
screening procedure and fear related to a cancer diagnosis. We
further broke down the latter category into three subthemes
that we grouped as follows: (1) fear of death, (2) fear of side
effects from treatment, and (3) fear of financial burden from
treatment. To address fear of dying, we included an attribute
indicating the survival rate if cancer were to be diagnosed. To
address fear of adverse effects, we included 2 attributes: the
fear of losing one’s breast (mammography DCE) and of infer-
tility (cervical cancer DCE). We also included an attribute
focusing on treatment costs conditional on a positive diagnosis.
We presented this cost in dollars as opposed to percentage
reductions as done in the prior DCE, as many women have no
idea of the actual costs of treatment and there is a wide range
depending on the approach taken. We also including a level
with a monetary incentive (ie, payment) for attending the
screening to see the impact of a cash payment on stated uptake.
We excluded screening frequency from the attribute list
because our aim was to analyze the preferences for screening
according to established guidelines. We also excluded travel time
because this factor was neither mentioned in our focus groups nor
likely to be relevant in a small city-state like Singapore. To further
reduce the number of attributes, we mapped pain (for
mammography) and sex of health practitioner (for Pap smear) to
the fear of screening procedure, and screening effectiveness to the
fear of dying. We confirmed our attribute selection and deter-
mined preliminary levels by means of 20 cognitive interviews.
Each cognitive interview took around 1 hour for the respondents
to complete either the breast or cervical cancer screening surveys.
Table 1 presents the 6 selected attributes along with their levels.
We finalized the attribute levels after conducting quantitative
pilots to ensure a sufficient degree of trading off betweenPap smear.
3 4
30%
rge Pay $50 Pay $200
65% 90%
eel and appearance of breast Lose an entire breast
$150 000 $250 000
30%
rge Pay $50 Pay $200
65% 90%
culties Infertility
$150 000 $250 000
Figure 1. Example of choice-task for mammography screening.
No change
$150,000 $150,000
b
How likely would you be to screen according to guidelines given all 6 aspects of 
your preferred scenario? 
Definitely
Definitely not
Likely
Unlikely
a
WHICH ONE WOULD YOU CHOOSE?
Discomfort or pain during
mammography
chance of false cancer
diagnosis
out-of-pocket payment or
reward
Discomfort Pain
15% chance of false
diagnosis
15% chance of false
diagnosis
Receive $50 Pay $200
IF breast cancer is
found and you
undergo treatment...
IF breast cancer is
found and you
undergo treatment...
50% survival 50% survivalChance of surviving breastcancer
permanent change to breast
Total out-of-pocket cost of
treatment
Lose an entire
breast
Scenario A
Scenario B
Out of these 2 scenarios, which one do you prefer?
For the next time you
screen...
For the next time you
screen...
1248 VALUE IN HEALTH SEPTEMBER 2020attributes. For chance of survival, we used a wide range of levels
consistent with the respondents’ beliefs regarding cancer survival.
Design of the Survey and the DCE
The surveys started by giving background information on
mammography or Pap smear screening. This was followed by
questions on past experience and perception of the cancer
screening services. We then asked respondents their beliefs about
screening costs and accuracy, cancer survival, the probability of
suffering from permanent side effects, and out-of-pocket treat-
ment costs. Participants were also asked about their opinion on
how painful mammography screening is and how important it is
to be able to choose the sex of the staff performing the Pap smear.
These questions were asked before the DCE. The attributes and
levels were then introduced to the respondents, followed by the
health promotion message for the treatment group.
Several focus group participants conveyed that screening is a
lose–lose proposition: a negative test is a waste of time and
money, whereas a positive test uncovers a life-threatening health
problem. In efforts to alter this perception and address the fear of
a positive diagnosis, we randomly selected one-half of the re-
spondents to be subjected to the following public health promo-
tion message: “Cancer screening according to guidelines is a
WIN-WIN. A negative test result gives peace of mind and early
detection saves lives.”
We presented 2 alternative screening scenarios per choice-
task. To maximize the information collected from each choice-
task, we used a 2-part question format. The first part was a
forced comparison between the 2 alternative scenarios, and the
second part asked for the likelihood of screening under the
preferred scenario. Responses “likely” and “definitely” were
grouped to indicate screening uptake in the main estimates and
assumed that only those who said “definitely would screen” were
tested in a sensitivity analysis. Figure 1 shows an example choicetask for mammography. Note that we clearly divided the attributes
into screening characteristics (first 3 attributes) and consequences
of being diagnosed with cancer (last 3 attributes).
We used SAS macros to generate D-efficient designs for our
model specifications,15 notably accounting for the interaction
terms between cancer survival and permanent adverse effects. We
included these interaction terms, as respondents might value
survival less if they were to suffer from permanent adverse effects.
Prior parameter values were all set to zero when generating the
designs. We obtained 72 choice tasks, which we divided into 9
blocks of 8 choice tasks to reduce the respondent burden. We then
randomly assigned an equal number of respondents to each block.
We also added 2 choice tasks in each block to test the transitivity
of the stated preferences.16,17 Transitivity requires that if Scenario
A is preferred to Scenario B and Scenario B is preferred to Scenario
C, then Scenario A should also be preferred to Scenario C. This is
one of the fundamental axioms of economic utility theory and a
requirement for rational preference.18
After administering the DCE, questions were asked on
perceived susceptibility and vulnerability to breast and cervical
cancer, health behaviors and attitudes, opinions regarding po-
tential public policies aimed at increasing screening uptake, health
status, and socio-demographics. Some of this information was
jointly analyzed with the focus group data in mixed-methods
exercises and published elsewhere.14 Before fielding, pilot sur-
veys were administrated to 40 eligible respondents. Because no
additional concerns were raised, we did not make any further
revisions. The average survey took about 30 minutes to complete.
Data Collection
To determine an acceptable sample size for each DCE, we used
Orme’s rule-of-thumb equation.19 This suggested we need at least
375 respondents for each DCE, which we rounded up to 400. The
sampling frames are nationally representative of the population of
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between 40 and 65 for mammography screening, and between 25
and 65 for Pap smear screening. Each sampling frame contained
1000 addresses to account for invalid addresses, ineligible
households, nonresponses, and other issues that may arise during
data collection. For households with multiple eligible women, a
Kish grid was used to select a respondent.20 The surveys were
administered by trained interviewers using computer tablets be-
tween September 2014 and June 2015. Appendix A (in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2020.06.
004) gives a detailed description of the model specification and
estimation method used.Results
Table 2 presents the characteristics of the mammography and
Pap smear respondents according to their past screening experi-
ence following the guidelines of every 2 years for mammography
and every 3 years for Pap smear. Mixed logit estimation parame-
ters are presented in Appendix Tables 2 and 3 (in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2020.06.004) for
mammography and Pap smear screening, respectively. We found
that screening cost was not statistically significant for mammog-
raphy (P = .25) or Pap smear (P = .67). Permanent adverse effects
were also not statistically significant for Pap smear at the 5% level.
In contrast, we found that all other attributes were statistically
significant for both screening services (all P , .01). All interaction
terms involving messaging equal to zero cannot be rejected (P
value of .11 for mammography and .34 for Pap smear). This means
that the message failed at significantly altering the choices made
by the respondents in the DCEs. The same statistical test con-
ducted for the income variable is strongly rejected for mammog-
raphy (P , .01) but cannot be rejected for Pap smear (P = .13). The
same statistical test also shows that past screening experiences
following the guidelines do not significantly affect screening de-
cisions in the DCEs (P value of .59 for mammography and P value
of .25 for Pap smear).
Tables 3 and 4 present changes in screening uptake according
to changes in attribute levels for mammography and Pap smear,
respectively. The uptake for mammography and Pap smear when
the attributes are set to their worst levels are 63.7% and 57.1%,
respectively. For both surveys, screening service attributes
(experience, accuracy, and cost) have the lowest effect sizes.
Improving mammography screening experience from painful to
having discomfort would increase uptake by 1.2 percentage points
(1.9%), whereas giving Pap smear respondents the choice of the
health practitioner’s sex would increase uptake by 2.5 percentage
points (4.4%). Decreasing the chance of a false diagnosis from 30%
to 5% would increase screening uptake by 1.4 percentage points
(2.1%) for mammography and by 0.7 percentage point (1.2%) for
Pap smear. Even replacing the $200 screening cost by a $50
monetary incentive would increase screening uptake by only 1
percentage point for both mammography and Pap smear.
Tables 3 and 4 reveal that, given the levels shown, treatment
outcomes in the case of a cancer diagnosis is what mattered most
to respondents. For both cancers, survival was the most important
attribute. Improving survival chances from 25% to 90%, an
admittedly large range but consistent with the difference between
early and late diagnosis, would increase mammography and Pap
smear screening uptake by 14.5 and 20.4 percentage points,
respectively—relative increases of 22.8% and 35.7%. Out-of-pocket
treatment cost was nearly as important to respondents. Reducingcosts from $250 000 to $0, as would occur with Universal Health
Coverage, would increase mammography and Pap smear
screening uptake by 14.3 and 19.3 percentage points, respectively,
which corresponds to an increase of 22.4% and 33.8%. Not losing a
breast would increase mammography screening uptake by 4.8
percentage points (7.5%), whereas avoiding infertility would in-
crease Pap smear screening uptake by 4.7 percentage points
(8.2%).
For both screening services, there was no noticeable difference
in attribute effect between the respondents who were subjected
to messaging and those who were not. For mammography, those
with lower income were relatively less concerned by cancer sur-
vival and permanent adverse effects but relatively more con-
cerned about treatment costs (P , .05), as reported in Appendix
Table 2 (in Supplemental Materials found at https://doi.org/10.1
016/j.jval.2020.06.004). For Pap smear, those with lower income
were relatively less concerned about screening accuracy (P , .05)
but income did not have a statistically significant effect on con-
cerns related to survival or treatment cost, as shown in Appendix
Table 3 (in Supplemental Materials found at https://doi.org/10.1
016/j.jval.2020.06.004). Past screening experiences also did not
have any statistically significant moderating effect.
In Table 5, we present the respondents’ opinions and beliefs on
the cancer screening attributes that were included in the DCEs.
What stands out is that respondents vastly underestimate survival
for screen-detected breast and cervical cancer. In our mammog-
raphy sample, 94.4% of non-screeners and 87.1% of screeners re-
ported that they believe the screen-detected breast cancer
survival rate is lower than 90%. In total, 82.2% of nonscreeners and
66.0% of screeners in our Pap smear sample believe that the
screen-detected cervical cancer survival rate is lower than 75%.
These are low compared with the survival estimates using the age-
standardized relative survival rates per cancer stage in
Singapore21 and the data on the stage distribution of screen-
detected breast and cervical cancers.22,23 These calculations yiel-
ded a survival rate of 93% for screen-detected breast cancer and
86% for screen-detected cervical cancer.
We simulated the effect of a fully successful information
campaign, focusing on survival conditional on early detection/
treatment, on cancer screening uptake. To do so, we first predicted
the uptake of each respondent by setting the attributes at their
believed levels. We then substituted the believed cancer survivals
with the actual survival and recalculated uptake. This simulation
found that, if misconceptions were corrected, mammography
screening would increase by 4.6 percentage points and Pap smear
screening would increase by 6.5 percentage points. On the other
hand, 79.5% of the mammography sample and 75.0% of the Pap
smear sample believed that they would suffer from permanent
adverse effects from cancer treatment. These beliefs were not
significantly different between screeners and non-screeners in the
mammography sample. However, among the Pap smear re-
spondents, a larger proportion of those who believe they would
have both sexual difficulties and inability to have children are from
the screener group. Therefore, correcting thesemisperceptionsmay
not translate into higher screening rates in the real world.
Lastly, Tables 3 and 4 show that fully subsidizing a $200
screening service would only increase uptake by 2.3 and 5.6
percentage points for mammography and Pap smear, respec-
tively. We calculated the increase in uptake that would corre-
spond to distributing the same total amount in subsidies to
lower the treatment cost of those diagnosed with cancer. To do
this, we first tested polynomial specifications for treatment cost,
chance of false diagnosis, and chance of cancer survival, and
Table 2. Respondent characteristics according to past screening experience.
Mammography Pap Smear
Screened
according to
guidelines
(n = 142)
Did not screen
according to
guidelines*
(n = 258)
Screened
according to
guidelines
(n = 206)
Did not screen
according to
guidelines†
(n = 195)
Citizenship (%)
Singapore citizen 92.3 86.4 81.1 79.0
Singapore permanent resident 7.8 13.6 18.9 21.0
Age, mean [SD] 52.9 [6.6] 51.7 [7.7] 42.5 [9.6] 43.6 [12.5]
Ethnicity (%)
Chinese 73.9 74.0 68.5 62.1
Malay 11.3 12.4 16.0 19.0
Indian 10.6 9.7 11.2 12.3
Other 4.2 3.9 4.4 6.7
Marital status‡
Never married 3.5 9.3 3.9 21.0
Married 85.9 81.0 92.2 71.8
Widowed/divorced/separated 9.2 7.8 3.4 5.1
Prefer not to say 1.4 1.9 0.5 2.1
Highest educational attainment‡,§
No formal education/primary 21.1 27.1 8.3 17.4
Secondary/vocational/ITE 38.7 46.1 34.0 37.4
JC/poly/diploma/university and above 40.1 26.7 57.8 45.1
Employment status (%)
Working full-time 40.9 34.1 56.8 47.7
Working part-time 18.3 17.8 13.1 14.4
Homemaker/retired or not working 40.9 48.1 30.1 38.0
Household total income per month, (%)‡,§
, $1500 11.3 15.5 5.3 16.4
$1500-$3499 15.5 24.0 23.3 24.6
$3500-$11499 37.3 28.3 45.2 27.2
. $11 500 10.6 2.7 8.3 3.1
Refused/don't know 25.4 29.5 18.0 28.7
Housing type‡,§
HDBk 1-3 room, (%) 20.4 20.2 18.5 30.8
HDBk 4 room 33.8 48.5 37.4 34.4
HDBk . = 5 room 26.8 22.9 29.6 25.1
Condo/private flat/bungalow/semiD/ Terrace/other 19.0 8.5 14.6 9.7
Current health status (%)
Excellent 6.3 3.5 4.4 3.1
Very good 17.6 12.8 17.0 19.0
Good 49.3 53.9 59.2 59.5
Fair 24.7 28.3 19.4 18.0
Poor 2.1 1.6 0.0 0.5
Ever been diagnosed for cancer, (%)§ 9.2 3.1 4.4 2.1
Go for regular check-up at least once in every 2 years, (%)‡,§ 88.0 55.8 86.9 46.2
HDB indicates Housing and Development Board, which offers public housing in Singapore.
*Did not screen according to guidelines includes those who never screened and those who screened at least once but had their last mammography more than 2 years
ago.
†Did not screen according to guidelines includes those who never screened and those who screened at least once but had their last Pap smear more than 3 years ago.
‡Statistically significant difference at the 5% level between screeners and non-screeners for Pap smear.
§Statistically significant difference at the 5% level between screeners and non-screeners for mammography.
kHDB stands for Housing and Development Board which offers public housing in Singapore.
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function for false diagnosis and cancer survival. Results from
these estimates are presented in Appendix Tables 4 and 5.
Linearizing our uptake effects on the range of treatment costs
considered, we found that uptake would increase by 0.7 and 2.3
percentage points for each $1000 reduction in treatment cost.
Given that the chance of testing positive during amammography or Pap smear amounts to 7.924 and 0.425 per
1000 screeners, respectively, a screening subsidy of $200 would
correspond to $200/0.0079 = $25253 and $200/0.0004 =
$540541 treatment subsidy for each screen-detected breast and
cervical cancer patient, respectively. In the case of cervical
cancer, our calculated subsidy of $540541 is more than the
highest cost level of $250 000 in our DCE. Thus, cervical cancer
Table 3. Change in mammography screening uptake according to changes in attribute levels (in percentage points).*,†
Attribute level All women Messaging Income‡ Screened according
to guidelines
No Yes Lower Higher No Yes
Reference scenario§ 63.7k 67.1k 61.2k 61.9k 67.7k 59.6k 69.4k
[55.9-70.8] [58.3-75.8] [52.5-69.5] [53.8-69.5] [58.3-77.5] [51.0-67.8] [60.1-77.9]
Discomfort during
screening (ref: pain)
1.2 1.2 1.4 1.1 1.2 1.4k 0.9
[0-2.8] [0-3.0] [0-3.3] [0-2.9] [0-3.3] [0.1-3.0] [20.3 to 2.6]
Chance of false
diagnosis (ref: 30%)
5% 1.4 1.2 1.5 0.4 2.9k 1.6 1.1
[0-3.5] [20.8 to 3.5] [20.3 to 3.9] [21.8 to 2.3] [0.8-5.8] [0-4.3] [21.1 to 3.5]
15% 0.6 0.2 1.1 1 20.2 0.8 0.3
[20.8 to 2.3] [22.0 to 2.3] [21.0 to 3.6] [20.8 to 3.3] [22.5 to 2.0] [21.0 to 3.0] [22.0 to 2.8]
Screening cost (ref: pay $200)
Receive $50 0.9 1.1 0.5 1.5 20.1 1.3 0.1
[20.5 to 2.8] [20.8 to 3.5] [21.3 to 2.8] [0-3.8] [22.5 to 2.3] [20.5 to 3.8] [22.3 to 2.3]
Free-of-charge 2.3k 2.6k 1.9 2.8k 1.4 2.5k 1.9
[0.8-4.3] [0.5-5.1] [0-4.5] [0.9-5.5] [20.3 to 3.8] [0.8-4.8] [0-4.3]
Pay $50 1.6k 2.1k 1 1.6 1.6 1.5 1.8
[0.3-3.5] [0.3-4.3] [20.5 to 3] [0-3.8] [0-3.8] [0-3.5] [0-4.0]
Chance of cancer
survival (ref: 25%)
90% 14.5k 14.3k 15k 14.1k 15.4k 15.4k 13k
[9.5-20] [9.3-19.8] [9.8-20.8] [9.1-19.4] [10.0-21.3] [10.3-21.0] [8.0-18.6]
65% 9.9k 8.9k 10.8k 10k 10k 10.2k 9.1k
[6-14.5] [5.3-13.5] [6.8-15.6] [6.3-14.4] [6.0-14.9] [6.0-14.8] [4.8-13.5]
50% 9.3k 9.6k 9.3k 9.4k 9.1k 10k 8.4k
[5.5-13.8] [5.5-14.3] [5.3-13.8] [5.4-13.6] [5.0-14.3] [5.8-14.5] [4.3-12.5]
Permanent side-effect
(ref: loss of an entire breast)
None 4.8k 6.3k 3.1 2.5 8.1k 4.7k 4.9k
[1.8-8.5] [2.8-10.4] [0-6.8] [20.3 to 6] [4.3-12.3] [1.3-8.6] [1.5-8.8]
Change in feel and appearance 2.1 2.7 1.8 0.5 4.6k 1.7 2.4
[20.3 to 5] [20.1 to 6.3] [21.0 to 5.3] [22.3 to 3.5] [1.0-8.5] [21.3 to 5.3] [20.3 to 5.8]
Out-of-pocket treatment
cost (ref: $250 000)
$0 14.3k 13.8k 14.7k 16.2k 11.6k 16.1k 11.6k
[10.1-19.1] [9.3-19.3] [10.5-20.3] [11.8-21.8] [7.3-17.1] [11.3-21.5] [7.5-16.8]
$50 000 10.3k 10.9k 9.4k 11.2k 9k 11.3k 8.5k
[6.8-14] [7.3-15.3] [5.8-13.8] [7.5-15.6] [5.5-13.3] [7.3-15.8] [5.1-12.8]
$150 000 4.3k 4.5k 4k 4.7k 4k 4.1k 4.6k
[2.0-7.0] [2.0-7.6] [1.5-7.3] [2.0-7.8] [1.3-7.0] [1.8-7.1] [1.8-7.9]
Note. N = 400 respondents.
*The incremental effects of each attribute were calculated by setting all other attributes at their reference level.
†Squared brackets indicate 95% simulated nonparametric confidence intervals.
‡Owing to the large proportion of missing income values, lower income was proxied by living in a HDB of 4 rooms or less, and higher income proxied by living in HDB of 5
rooms or more, private flat, condo, or landed property.
§The reference scenario takes the worst level of all the attributes: pain, 30% chance of false diagnosis, $200 screening cost, 25% survival rate, lose an entire breast, $250K
OOP cost of treatment.
kIndicates statistical significance at the 5% level.
PREFERENCE-BASED ASSESSMENTS 1251treatment was fully subsidized, whereas breast cancer treatment
was only partially subsidized in our simulations. The resulting
increase in uptake would be 17.7 percentage points for
mammography and 19.3 percentage points for Pap smear. The
much larger effect for Pap smear is due to the relatively lower
cervical cancer detection rate.Discussion
Our DCEs revealed that respondents were far more concerned
about cancer treatment outcomes than they were about screening
service features, including screening cost, given the range of levels
shown. For instance, although screening subsidies had a negligible
Table 4. Change in Pap smear screening uptake according to changes in attribute levels (in percentage points).*,†
Attribute level All women Messaging Income‡ Screened according to
guidelines
No Yes Lower Higher No Yes
Reference scenario§ 57.1k 54.1k 59.4k 61.4k 52.8k 54k 60.7k
[48.6-65.6] [43.3-64.8] [47.9-68.8] [51.3-70.1] [41.4-63.5] [43.8-64.1] [49.8-70.0]
Choice of practitioner’s gender (ref: no) 2.5 3.7 1.4 2.4 2.1 3.5* 1.7
[0-5.3] [0.5-6.8] [21.8 to 4.3] [20.3 to 5.3] [20.8 to 5.3] [0.3-6.8] [21.3 to 4.8]
Chance of false diagnosis (ref: 30%)
5% 0.7 1.5 20.1 20.3 2.3 1.3 -0.2
[21.8 to 3.3] [21.5 to 4.8] [23.0 to 3.3] [23.0 to 2.3] [21.0 to 6.0] [21.8 to 4.6] [23.3 to 2.8]
15% 1.2 1.8 0.4 0.2 2.8 1.2 1.1
[21.0 to 3.8] [21.3 to 5.3] [22.5 to 3.8] [22.5 to 3.0] [20.3 to 6.8] [21.8 to 4.8] [21.9 to 4.5]
Screening cost (ref: pay $200)
Receive $50 1 1.6 0.4 20.7 3.2 0.5 1.1
[21.0 to 3.8] [21.5 to 5.0] [22.8 to 3.8] [23.8 to 2.0] [0-7.0] [22.8 to 4.0] [22.0 to 4.4]
Free-of-charge 5.6k 6.2k 5.1k 3.5k 8.2k 5k 6.1k
[2.5-9.0] [2.5-10.0] [2.0-9.0] [0.8-6.8] [4.3-12.5] [1.5-8.8] [2.8-10.0]
Pay $50 3k 2.9k 3.1k 1.6 5k 2.7k 3.3k
[0.8-5.8] [0.3-5.8] [0.5-6.3] [20.6 to 4.0] [2.0-8.5] [0.3-5.5] [0.8-6.5]
Chance of cancer survival (ref: 25%)
90% 20.4k 19.7k 21.1k 17.6k 23.4k 19.5k 21.1k
[14.6-27.4] [13.3-26.6] [13.8-28.6] [11.3-24.5] [16.4-31.0] [13.0-26.4] [14.0-28.5]
65% 14.5k 14.7k 14.4k 12.8k 15.3k 12.7k 16.2k
[9.5-20.3] [9.0-20.5] [8.8-20.9] [7.8-18.8] [9.5-21.6] [7.3-18.8] [10.3-22.5]
50% 11.6k 11.4k 11.6k 9.8k 13.6k 10.9k 12.2k
[6.8-17.3] [6.0-17.5] [5.9-17.6] [4.8-15.5] [8.0-20.3] [5.8-16.8] [6.8-18.5]
Permanent side-effect (ref: infertility)
None 4.7k 3.9 5.4k 4.9k 4 4.7k 4.4
[0.5-9.8] [20.3 to 9.3] [0.8-10.9] [0.5-9.8] [20.5 to 9.8] [0.3-10.1] [0-9.8]
Sexual difficulties 1.9 0 3.7 2 0.9 1.4 2.4
[22.1 to 6.3] [25.3 to 5.4] [20.5 to 9.0] [22.0 to 6.8] [24.5 to 6.3] [23.3 to 6.5] [22.0 to 7.3]
Out-of-pocket treatment cost (ref: $250k)
$0 19.3k 20.3k 18.6k 18.2k 18.7k 19.3k 19k
[14.5-25.1] [14.5-26.9] [12.8-25.1] [13.3-24.4] [13.0-25.5] [13.6-25.9] [13.4-25.8]
$50k 15.7k 14.4k 16.8k 13.5k 16.6k 14.8k 15.9k
[11.3-21.3] [9.8-19.8] [11.5-22.6] [9.0-18.5] [11.8-22.5] [9.8-20.0] [11.0-21.5]
$150k 6.5k 5.4k 7.6k 5.1k 8.2k 6.2k 6.6k
[3.5-9.8] [2.0-9.4] [3.8-11.8] [2.0-8.5] [4.3-12.8] [2.8-10.3] [2.8-10.8]
Note. N = 401 respondents.
*The incremental effects of each attribute were calculated by setting all other attributes at their reference level.
†Squared brackets indicate 95% simulated nonparametric confidence intervals.
‡Owing to the large proportion of missing income values, lower income was proxied by living in a HDB of 4 rooms or less, and higher income proxied by living in HDB of 5
rooms or more, private flat, condo, or landed property.
§The reference scenario takes the worst level of all the attributes: pain, 30% chance of false diagnosis, $200 screening cost, 25% survival rate, lose an entire breast, $250
000 out-of-pocket cost of treatment.
kIndicates statistical significance at the 5% level.
1252 VALUE IN HEALTH SEPTEMBER 2020influence on uptake, an increase in perceived cancer survival rate
from 25% to 90% led to increases in predicted uptakes in
mammography and Pap smear of 23% and 36%, respectively.
Although public health agencies cannot directly influence the
survival rate, they can address misconceptions about survival,
which our results suggest would have a positive influence on
screening uptake. Likewise, a decrease in treatment costs from
$250 000 to $0 led to similar increases in predicted uptakes. These
results occur because women greatly fear the costs of treatment
conditional on a positive diagnosis. Therefore, insulating womenfrom these costs has a large effect. Although such a strategy
sounds expensive, it is potentially less expensive than screening
subsidies because screening leads to few positive diagnoses,
especially for Pap smear.25
We expected our gain-framed message to partially address
women’s fears about screening. Even though this message was
based on prior research conducted in Singapore, the message
failed to improve screening uptake. While this message was tested
using stated preferences, its lack of effectiveness on intent to
screen makes it even less likely to work in the real world.
Table 5. Respondent opinions and beliefs on real cancer screening attributes.
Mammography Pap smear
Screened
according to
guidelines
(n = 142)
Did not screen
according to
guidelines*
(n = 258)
Screened
according to
guidelines
(n = 206)
Did not screen
according to
guidelines†
(n = 195)
Perception of pain during mammography, (%) 33.8 34.1
Will never get a pap smear if it is not
done by a healthcare professional
of my preferred gender, (%)
15.2 22.6
Chance of false diagnosis, (%)
,10% 44.1 43.8 52.7 41.1
10-25% 29.7 25.0 25.8 29.8
.25% 26.2 31.3 21.5 29.0
Screening cost, (%)‡,§
Free 19.1 15.3 10.8 8.9
,$25-49 44.9 22.2 56.0 21.8
$50-$99 23.8 12.5 16.6 4.0
$100-$199 5.9 4.9 7.2 8.1
.$200 0.8 1.4 0.4 0.8
Never heard of mammography/ pap smear 0.0 22.2 0.0 41.9
Don't know 5.5 21.5 9.0 14.5
Chance of survival‡,§
,10% 7.0 12.5 10.5 11.3
10-25% 7.8 5.6 10.1 9.7
25-50% 13.7 22.2 15.5 22.6
50-75% 32.0 38.9 30.0 38.7
75-90% 26.6 15.3 22.4 12.1
.90% 12.9 5.6 11.6 5.7
Permanent changes to breast after cancer treatment, (%)
No change 20.7 20.1
Change in the appearance and feel 39.8 39.6
Lose an entire breast 39.5 40.3
Permanent changes after cervical cancer treatment, (%)
No change 25.6 25.0
Sexual difficulties 7.6 4.8
Unable to have children 27.4 39.5
Both sexual and reproductive difficulties 39.4 30.7
OOP cost of treatment, (%)
$5000 46.9 45.8 34.3 40.3
$5,000-$19,999 21.5 27.8 27.4 32.3
$20,000-$49,999 15.2 15.3 21.3 16.9
.$50,000 16.4 11.1 17.0 10.5
*Did not screen according to guidelines includes those who never screened and those who screened at least once but had their last mammography more than 2 years
ago.
†Did not screen according to guidelines includes those who never screened and those who screened at least once but had their last Pap smear more than 3 years ago.
‡Statistically significant difference at the 5% level between screeners and non-screeners for mammography.
§Statistically significant difference at the 5% level between screeners and non-screeners for Pap smear.
PREFERENCE-BASED ASSESSMENTS 1253Although other messages may work better, our results suggest
that a very general message on survival may not be as effective as
properly informing women on actual cancer treatment outcomes
conditional on an early diagnosis. This is especially true in
Singapore, where respondents widely underestimated screen-
detected cancer prognosis. We estimated that correcting mis-
beliefs on screen-detected cancer prognosis has the potential to
increase mammography and Pap smear screening uptake by 4.6
and 6.5 percentage points, respectively. Another health promotion
strategy we propose is subsidizing treatment costs contingent on
screening according to guidelines. Our results show that this
strategy would be more effective than subsidizing screening costs.
Therefore, we propose limiting screening subsidies but ensuringthat cancer treatments are priced lower for those who screen
according to guidelines. Some screening subsidies may still be
needed, but these could be means-tested instead of being broadly
distributed.
A methodological point that we would like to highlight is that
DCEs do not require respondents to calculate expected utilities
accurately. DCEs merely require that respondents have a utility
associated with each attribute level and consistently tradeoff be-
tween them. When assessing the utility of treatment attributes,
the respondents were reminded that these were conditional on
testing positive for cancer, and rigorous pretesting made sure that
respondents were aware of this assumption. It is true that the
respondents’ utilities for treatment attributes implicitly includes
1254 VALUE IN HEALTH SEPTEMBER 2020an assessment of the probability of testing positive for cancer.
However, this probability does not have to be accurate. According
to prospect theory,26 it is the probability perceived by the re-
spondents, not the actual probability, that determines the choices
they make in reality.
As for limitations, DCEs have been criticized for their cognitive
burden and design matters such as framing, realism, and inter-
pretation of the opt-out parameter.27,28 We mitigated these limi-
tations through pretesting and by including choice-tasks to check
for violations of axioms of preference theory. Results show that
the full sample and subsample of those who passed these tests
yielded similar results (see Appendix Tables 6 and 7 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2020.06.
004). Further, it may be argued that by asking about both
screening and treatment outcomes simultaneously, our DCE de-
signs brought increased complexity and cognitive burden and
more attention to cancer treatment outcomes than many women
consider in reality. Whereas this may be true, the decision of
whether or not to undergo a screening exam is multifaceted, and
our focus group data clearly show that women consider both
screening and treatment attributes in deciding whether or not to
undergo a screening exam. Although we admit that framing likely
influenced responses, this is not unique to DCEs because real
world decisions are also subject to influence based on how in-
formation is presented. This is why our proposed policy strategies
involve increasing the salience of factors that might not be salient
enough in reality—but as we know from our DCEs, greatly matter
to women when they are paying attention. In other words, we
recognize that framing matters and propose to take advantage of
this to increase uptake in the real world. Other limitations are that,
based on the pretesting results, the respondents struggled with
trading off between attributes when survival was expressed as 5-
year survival rates; hence, survival was presented as “not dying as
a result of the disease” in the final DCE. This may have created a
slight discrepancy from the information available on actual (5-
year) survival rates. Another concern is that, despite using attri-
bute levels for chance of survival that are close to the respondents’
beliefs, we recognize that the range of survival rate options pre-
sented in the DCE might have magnified the importance of this
attribute, and thus the relative importance of treatment versus
screening. It is also worth noting that although our experimental
design made the gain-frame salient only to those respondents in
the treatment group, it is possible that some control group re-
spondents were exposed to gain-frame messaging before the
study and that some of them remembered it. Therefore, the
generalizability of the lack of effect with gain-frame messaging
should be considered limited to settings in which gain-frame
messaging is already in place. Lastly, this analysis took place in
Singapore, where participants are used to large out-of-pocket
expenses. Some results may not generalize to countries where
citizens are insulated from the costs of treatment.
Future research could entail developing and empirically
testing health promotion interventions according to the strate-
gies we propose above. Messaging on the fear of being diagnosed
with cancer could be included into letters inviting people to take
part in screening programs. Advertisements featuring screen-
detected cancer survivors sharing their treatment experience
could also be used to convey these messages. Regarding
screening-contingent cancer treatment subsidies, these could be
implemented as a special type of financial incentive for health
behavior change and tested in the framework of a randomized
controlled trial.29 There are numerous possibilities to test or
implement our findings that, ultimately, cancer screening is not
solely about screening, but also about the costs and benefits of
treatment.Supplemental Material
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